Reducing Risk for CV Outcomes

Slides:

Advertisements

Similar presentations

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Advertisements

NICE –CG 181 Continuum of CVD Risk and its treatment

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the FOURIER Trial Sabina A. Murphy,

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Back to the Basics of Dyslipidemia

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

Obesity and Dyslipidemia: How Would You Treat?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statin Selection in Special Patient Populations: A Case Challenge

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

CV Risk Doesn't End in the Cath Lab

Personalizing Statin Therapy in Patients With HIV

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Statins and HIV:.

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

CV Risk Doesn't End in the Cath Lab

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Elevated Admission Plasma Glucose Following ACS

Factor Xa Inhibitors in Coronary Artery Disease

DECLARE-TIMI 58.

A Family Affair.

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Omega-3s vs Pure EPA in Clinical Practice

Achieving Lipid Targets With PCSK9 Inhibition

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Reducing Risk for CV Outcomes

Program Goals

GLAGOV Evolocumab vs Placebo in Statin-Treated Patients

GLAGOV Impact of PCSK9i on Coronary Disease Progression

Effects of Lipid Lowering by PCSK9 mAbs on Inflammation in FH

Potential Benefits of Very Low LDL-C Levels

FOURIER Evolocumab vs Placebo in Statin-Treated Patients

FOURIER Primary and Secondary Efficacy Endpoints

FOURIER Key Subgroups

FOURIER Safety

Clinical Implications of FOURIER

SPIRE Trials Bococizumab vs Placebo in High-Risk Patients

SPIRE-1 and SPIRE-2 Confirmation of Attenuation in LDL-C Reduction Over Time

SPIRE Bococizumab CV Outcomes

Access to Nonstatin LLTs for High-Risk Patients

Algorithm: Treatment of HeFH and Clinical ASCVD With PCSK9 Inhibitors

Improving Access to PCSK9 Inhibitors

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)